In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:

• The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ART
• Updates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48
• The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutations

Presenter:

Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier, Jr., MD Education Director and Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Medical Director
Care Point Health and Wellness
Tallahassee, Florida

Link to the full program:
https://bit.ly/49x0W6D

Link to the slideset: 
https://bit.ly/4bzZoth

To get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.